Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DNL952 in adults with late-onset Pompe disease
NL-OMON61192Phase 2Not yet recruiting
- Sponsor
- Denali Therapeutics Inc.
- Start
- Aug 2026
- Modality
- Replacement Enzymes → Therapeutic Enzymes → Recombinant Proteins and Enzymes, Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of DNL952 in Pompe disease (6 cohorts), sponsored by Denali Therapeutics Inc. Primary endpoints: Incidence, severity, and seriousness of treatment-emergent adverse events and Incidence and severity of infusion-related reactions. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
DNL952
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NL-OMON61192.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61192.